Medal of Honor recipient praises revolutionary neck injection treatment for PTSD - Lebanon news - أخبار لبنان

Medal of Honor recipient praises revolutionary neck injection treatment for PTSD

Medal of Honor recipient praises revolutionary neck injection treatment for PTSD

A therapy for post-traumatic stress disorder that some doctors believe will “revolutionize the way PTSD is handled” was the subject of a recent “60 Minutes” report featuring a number of afflicted veterans, including one Medal of Honor recipient.

The breakthrough treatment, called stellate ganglion block, or SGB, has been shown to significantly diminish various symptoms of PTSD, such as depression, anxiety, and insomnia.

By injecting an anesthetic that numbs a bundle of nerves at the base of the neck, the SGB treatment dulls the area that serves as the body’s “fight or flight” response transmitter, providing instantaneous relief from some of the epidemic’s most chronic symptoms.

The shot, which was initially used to treat women experiencing menopausal hot flashes, is meticulously administered using ultrasound imagery to track the injection’s precision. Its results, meanwhile, are almost immediate and can last for months.

“I feel like a million pounds was taken off me,” Medal of Honor recipient and Marine veteran Dakota Meyer told “60 Minutes” immediately after being administered one of the shots.

“The best analogy I got for you is, like, if you took from being downtown New York City in rush hour traffic to, all of a sudden, driving down a quiet country road with nowhere to be.”

Meyer was in Kunar Province, Afghanistan, in September 2009, when a patrol he was providing security for was ambushed by more than 50 enemy fighters.

Realizing the team’s exit had been cut off, Meyer made five trips into the ambush zone over a period of six hours, braving walls of enemy fire each time to save as many pinned down personnel as he could.

Sign up for the Early Bird Brief Get the military’s most comprehensive news and information every morning


Enter a valid email address (please select a country) United States United Kingdom Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, The Democratic Republic of The Cook Islands Costa Rica Cote D’ivoire Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guinea Guinea-bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Moldova, Republic of Monaco Mongolia Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory, Occupied Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia and Montenegro Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand Timor-leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States United States Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Viet Nam Virgin Islands, British Virgin Islands, U.S. Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe

Thanks for signing up!


By giving us your email, you are opting in to the Early Bird Brief.

“He would tell us that he was not able to get the war out of his head,” 60 Minutes correspondent Bill Whitaker said of Meyer’s time since that hellish day.

“He brought it home with him. He was tense, he was anxious. He was quick to anger. He was losing his friends.”

But after receiving the injection by current doctor and former Navy SEAL Sean Mulvaney, a relieved Meyer felt “normal.”

Nearly 3 million service members like Meyer have deployed in support of American war operations since 2001. Of those who deployed to Iraq or Afghanistan, approximately 14 percent to 20 percent suffer from post-traumatic stress disorder.

And while SGB is not designed to get rid of memories associated with the trauma veterans have endured, it will significantly calm the way an afflicted individual responds to those thoughts. Thus, improving responsiveness to other forms of therapy, the “60 Minutes” study claimed.

Previous studies of small participant groups have backed up such proclamations.

In 2014, for example, a study in the “Military Medicine” journal found that just one week after the first SGB injection, nearly 80 percent of study participants experienced significant relief from PTSD symptoms.

Two years later, the Army received a $2 million grant from the Department of Defense to begin a randomized, three-year study to test the effects of the treatment on a group of 240 veterans afflicted by PTSD.

That study is set to conclude sometime this year.

Watch the full “60 Minutes” report on SGB below.

leave a reply



error: Content is protected !!